Trials (Sep 2024)

Role of the screening with coronary computed tomography angiography on lipid management and risk factors control in an asymptomatic Chinese population: a community-based, parallel-group, open-label, randomized clinical trial (RESPECT2)

  • Xiang Guo,
  • Jianhua Li,
  • Ying Zhu,
  • Yanming Li,
  • Jingzhou Jiang,
  • Rui Zuo,
  • Wei Xu,
  • Junqing Ma,
  • Chao Li,
  • Jialuo Yang,
  • Yuting Liu,
  • Minjie Zhao,
  • Di Tian,
  • Xinran Wang,
  • Jinwei Sun,
  • Bingqian Wu,
  • Conghong Wang,
  • Pengfei Jiang,
  • Jun Zhang,
  • Jian Zhong,
  • Changsheng Zhou,
  • Dongna Yi,
  • Xueqin Bao,
  • Jun Cai,
  • Yingqi Chen,
  • Xiaoqing Cheng,
  • Haowen Gong,
  • Yongyue Wei,
  • Yuxiu Liu,
  • Long Jiang Zhang

DOI
https://doi.org/10.1186/s13063-024-08469-z
Journal volume & issue
Vol. 25, no. 1
pp. 1 – 11

Abstract

Read online

Abstract Background Lipid management based on cardiovascular risk level is the cornerstone of primary prevention of coronary artery disease (CAD), while the accuracy and adherence of traditional cardiovascular risk stratification have been questioned. Prevention strategies based on imaging screening for atherosclerotic plaques are found to be more objective and adherent in recent studies. This trial aims to investigate the role of coronary computed tomography angiography (CCTA) in guiding the primary prevention of CAD in a randomized controlled design. Methods Approximately 3400 middle-aged asymptomatic community participants will be recruited and randomized in a 1:1 ratio to a traditional cardiovascular risk score-guided (usual care group) or CCTA-guided (CCTA group) strategy. Participants with cardiovascular disease, prior lipid-lowering therapy, CCTA contraindication, or serious diseases that affect life span will be excluded. The intervention strategy includes blood pressure, blood glucose, and lipid management and lifestyle modifications. Blood pressure and glucose targets and lifestyle modification recommendations keep the same in both strategies, while lipid management is personalized based on traditional risk level or CCTA results, respectively. The primary outcome is the proportion of participants taking lipid-lowering medication regularly at both 6 and 12 months. The secondary outcomes include the proportion of participants achieving low-density lipoprotein cholesterol lowering targets at 12 months, mean changes in lipid levels from baseline to 12 months, barriers to adherence, adverse reactions related to CCTA examination, and cardiovascular events. Discussion The study is the first randomized clinical trial to examine the effectiveness of a CCTA-guided versus a traditional risk score-guided primary prevention strategy in an asymptomatic community-based population. Trial registration ClinicalTrials.gov NCT05725096. Registered on 2 February 2023.

Keywords